First Trust NYSE Arca Biotechnology Index Fund (FBT)
|Ex-Dividend Date||Sep 23, 2015|
|Day's Range||163.67 - 165.71|
|Inception Date||Jun 19, 2006|
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Top 10 Holdings34.87% of assets
|Charles River Laboratories||CRL||3.48%|
|Sep 23, 2015||$0.0197||Sep 30, 2015|
|Jun 24, 2015||$0.0649||Jun 30, 2015|
|Mar 25, 2015||$0.0476||Mar 31, 2015|
|Dec 23, 2014||$0.0524||Dec 31, 2014|
Smart Beta ETF report for FBT
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...
The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, ...
As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on Inves...
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
Healthcare is one of the most politically sensitive sectors and that sensitivity is on full display in recent weeks with biotechnology ETFs, including the First Trust NYSE Arca Biotechnology Index Fund ...
Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.
Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ignor...
AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.
These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.